PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Pre-exposure prophylaxis (PrEP) is highly effective and an important prevention tool for African adolescent girls and young women (AGYW), but adherence and persistence are challenging. PrEP adherence support strategies for African AGYW were studied in an implementation study. Methods and findings: HIV Prevention Trials Network (HPTN) 082 was conducted in Cape Town, Johannesburg (South Africa) and Harare (Zimbabwe) from October 2016 to October 2018 to evaluate PrEP uptake, persistence, and the effect of drug level feedback on adherence. Sexually active HIV–negative women ages 16–25 were offered PrEP and followed for 12 months; women who accepted PrEP were randomized to standard adherence support (counseling, 2-way SMS, and adherence clubs) or enhanced adherence support with adherence feedback from intracellular tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS). PrEP uptake, persistence through 12 months (no PrEP hold or missed visits), and adherence were assessed. The primary outcome was high adherence (TFV-DP ≥700 fmol/punch) at 6 months, compared by study arm. Of 451 women enrolled, median age was 21 years, and 39% had curable sexually transmitted infections (STIs). Most (95%) started PrEP, of whom 55% had uninterrupted PrEP refills through 12 months. Of those with DBS, 84% had detectable TFV-DP levels at month 3, 57% at month 6, and 31% at month 12. At 6 months, 36/179 (21%) of AGYW in the enhanced arm had high adherence and 40/184 (22%) in the standard adherence support arm (adjusted odds ratio [OR] of 0.92; 95% confidence interval [CI] 0.55, 1.34;p= 0.76). Four women acquired HIV (incidence 1.0/100 person-years), with low or undetectable TFV-DP levels at or prior to seroconversion, and none of whom had tenofovir or emtricitabine resistance mutations. The study had limited power to detect a modest effect of drug level feedback on adherence, and there was limited awareness of PrEP at the time the study was conducted. Conclusions: In this study, PrEP initiation was high, over half of study participants persisted with PrEP through month 12, and the majority of young African women had detectable TFV-DP levels through month 6 with one-fifth having high adherence. Drug level feedback in the first 3 months of PrEP use did not increase the proportion with high adherence at month 6. HIV incidence was 1% in this cohort with 39% prevalence of curable STIs and moderate PrEP adherence. Strategies to support PrEP use and less adherence-dependent formulations are needed for this population. Trial registration: ClinicalTrials.gov NCT02732730.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.
Nel, A., van Niekerk, N., Kapiga, S., Bekker, L.-G., Gama, C., Gill, K., Kamali, A., Kotze, P., Louw, C., Mabude, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602046 · Cited by 479
Self-citationAhmed, K., Baeten, J. M., Beksinska, M., Bekker, L.-G., Bukusi, E. A., Donnell, D., Gichangi, P. B., Heller, K. B., Hofmeyr, G. J., Justman, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31288-7 · Cited by 299
Self-citation
Cited by
Mugwanya, K. K., Palayew, A., Schaafsma, T., Irungu, E. M., Bukusi, E., Mugo, N., Morton, J., Odoyo, J., Ngure, K., Baeten, J. M., et al. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26137 · Cited by 16
Self-citationStanton, A. M., O'Cleirigh, C., Knight, L., Davey, D. L. J., Myer, L., Joska, J. A., Mayer, K. H., Bekker, L., & Psaros, C. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.26026 · Cited by 13
“In a recent study, only one in five participants had high adherence (defined as tenofovir diphosphate concentrations [TFV-DP] ≥ 700 fmol/punch) over the first 6 months [36].”
BackgroundSelf-citation
Metadata
- Authors
- Celum, C., Hosek, S., Tsholwana, M., Kassim, S., Mukaka, S., Dye, B. J., Pathak, S., Mgodi, N., Bekker, L.-G., Donnell, D. J., Wilson, E., Yuha, K., Anderson, P. L., Agyei, Y., Noble, H., Rose, S. M., Baeten, J. M., Fogel, J. M., Adeyeye, A., Wiesner, L., Rooney, J., & Delany-Moretlwe, S.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-18
- Volume
- 18
- Issue
- 6
- Pages
- e1003670
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W3170023264
- Cited by
- 178
- References
- 3
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1003670
- The paper
- Celum, C., Hosek, S., Tsholwana, M., Kassim, S., Mukaka, S., Dye, B. J., Pathak, S., Mgodi, N., Bekker, L.-G., Donnell, D. J., Wilson, E., Yuha, K., Anderson, P. L., Agyei, Y., Noble, H., Rose, S. M., Baeten, J. M., Fogel, J. M., Adeyeye, A., . . . Delany-Moretlwe, S. (2021). PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1003670
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.